# Western Region Account Research & New Logo Opportunities
**February 2026 | Deep Research Analysis**

---

## Executive Summary

This research covers 16 priority Western region biotech targets and identifies 20+ new logo opportunities matching USDM GTM triggers. Key findings:

**Major Events Discovered:**
- üî¥ **Sana Biotechnology** - Securities fraud lawsuit filed (May 2025), significant legal/compliance concerns
- üü¢ **Tune Therapeutics** - $175M Series B (Jan 2025), new CEO, clinical trial approved in Hong Kong
- üü¢ **Cellares** - $257M Series D (Jan 2026), FDA AMT designation, major expansion
- üî¥ **Capstan Therapeutics** - ACQUIRED by AbbVie (Aug 2025) - remove from target list
- üü¢ **National Resilience** - $825M financing (Oct 2025), new CEO, major facility expansion
- üü¢ **GRAIL** - Pathfinder 2 results (Oct 2025), 7x cancer detection improvement
- üü¢ **64x Bio** - AAV Apex Suite launch (Jun 2025), manufacturing platform
- üü¢ **Deep Genomics** - REPRESS AI model launch (May 2025), executive hires
- üü¢ **Freenome** - Roche partnership, Exact Sciences license, going public via SPAC

---

## Part 1: Target Account News Analysis

### Seattle/Pacific Northwest

#### 1. Sana Biotechnology üî¥ HIGH RISK
**Location:** Seattle, WA  
**Status:** Public (NASDAQ: SANA)

**Recent News (Last 6 Months):**
- **May 2025**: Multiple securities fraud class action lawsuits filed
  - Rosen Law Firm, Levi & Korsinsky, Gross Law Firm all filing
  - Covers purchases between March 17, 2023 and November 4, 2024
  - Lead plaintiff deadline: May 20, 2025
- Mentioned in CAR T-cell therapy market reports as active player
- Mentioned in CRISPR market projections

**GTM Alignment:**
| Trigger | Status |
|---------|--------|
| Regulatory Pressure | ‚ö†Ô∏è HIGH - Securities litigation indicates potential compliance issues |
| AI Governance | ‚ÑπÔ∏è Moderate - Cell therapy requires AI/ML for manufacturing |
| Platform Transitions | ‚ùì Unknown |
| Clinical Scale-up | ‚úÖ Active clinical programs |

**Outreach Recommendation:** ‚ö†Ô∏è CAUTION - Legal situation creates risk but also potential QC/compliance consulting needs. Monitor closely.

---

#### 2. Tune Therapeutics üü¢ HOT PROSPECT
**Location:** Durham, NC (HQ) with research operations  
**Status:** Private, Series B complete

**Recent News (Last 6 Months):**
- **March 2025**: Named John McHutchison as CEO and Chairman (industry veteran from Gilead)
- **January 2025**: Completed $175M+ Series B financing - significantly oversubscribed despite gene editing market downturn
- **January 2025**: Received Hong Kong approval to initiate clinical trial for TUNE-401 (HepB epigenetic silencer)
- **November 2024**: AASLD data showing near-complete HepB repression
- Active pipeline with first-in-class epigenetic silencer approaching clinic

**GTM Alignment:**
| Trigger | Status |
|---------|--------|
| Recent Funding | ‚úÖ $175M Series B - Jan 2025 |
| Clinical Scale-up | ‚úÖ Moving to clinic in 2025 |
| Leadership Changes | ‚úÖ New CEO March 2025 |
| GxP Needs | ‚úÖ Clinical manufacturing requires GxP systems |
| Platform Transitions | ‚ùì Likely implementing systems for clinical stage |

**Outreach Recommendation:** üî• TOP PRIORITY - Perfect timing with new CEO, fresh funding, and clinical trials starting. GxP/QC needs imminent.

---

#### 3. Outpace Bio
**Location:** Seattle, WA (700 Dexter Ave N)  
**Status:** Private

**Recent News:**
- Active in cell therapy space
- Collaborating with leading biopharma and academics
- Focus on making cell therapies more effective and safe

**GTM Alignment:**
| Trigger | Status |
|---------|--------|
| Cell Therapy Scale-up | ‚úÖ Core focus area |
| GxP Needs | ‚úÖ Cell therapy requires GxP |

**Outreach Recommendation:** üü° MODERATE - Monitor for funding announcements.

---

#### 4. Umoja Biopharma
**Location:** Seattle, WA  
**Status:** Private

**Recent News:**
- **November 2025**: Expanded collaboration with Nona Biosciences for in vivo CAR-T
- Mentioned as board observer company for Two Bear Capital (Sep 2025)
- Active in novel CAR T-cell therapy development
- Collaboration with Harbour BioMed for research

**GTM Alignment:**
| Trigger | Status |
|---------|--------|
| Cell Therapy Scale-up | ‚úÖ In vivo CAR-T is cutting edge |
| Partnerships | ‚úÖ Multiple active collaborations |
| GxP Needs | ‚úÖ Manufacturing complex therapies |

**Outreach Recommendation:** üü° MODERATE - Growing partnership activity suggests expansion. Monitor for Series C.

---

#### 5. A-Alpha Bio
**Location:** Seattle, WA  
**Status:** Private

**Note:** Limited recent news found. Website appears to have changed or company may have pivoted.

**Outreach Recommendation:** ‚ö™ LOW PRIORITY - Requires additional research on current status.

---

#### 6. Aurion Biotech üü¢ SOLID PROSPECT
**Location:** Seattle, WA  
**Status:** Private

**Recent News:**
- Mentioned in Persistent Corneal Edema market reports (projected 21.8% CAGR growth)
- Active in cell therapy market (projected to reach $29.5B by 2032)
- Focus on corneal endothelial cell therapy

**GTM Alignment:**
| Trigger | Status |
|---------|--------|
| Cell Therapy | ‚úÖ Regenerative medicine focus |
| FDA Pathway | ‚úÖ Likely pursuing BLA |

**Outreach Recommendation:** üü° MODERATE - Solid cell therapy play, monitor for clinical milestones.

---

### San Francisco Bay Area

#### 7. Atomwise ‚Üí Numerion Labs (REBRANDED)
**Location:** San Francisco, CA  
**Status:** Rebranded/Pivoted to Numerion Labs

**Recent Discovery:**
- Atomwise website now redirects to **Numerion Labs**
- Focus on ML-powered drug discovery
- Small-molecule drugs for immune and inflammatory diseases
- "AI superplatform" for novel molecule discovery

**GTM Alignment:**
| Trigger | Status |
|---------|--------|
| AI Governance | ‚úÖ Core AI/ML platform company |
| Drug Discovery AI | ‚úÖ Primary business model |

**Outreach Recommendation:** üü° UPDATE TARGET LIST - Research Numerion Labs status and funding.

---

#### 8. Deep Genomics üü¢ HOT PROSPECT
**Location:** Toronto/Cambridge (operates in Bay Area ecosystem)  
**Status:** Private

**Recent News:**
- **May 2025**: Launched REPRESS AI foundation model for RNA biology
  - Predicts microRNA binding and mRNA degradation
  - Major platform expansion
- **April 2025**: Key executive hires announced
  - Monika Kowalczyk, MD, PhD joined as executive
  - Strengthening R&D leadership
- Named TechBio leader, won Stevie Award 2024 for Biotechnology Company of the Year

**GTM Alignment:**
| Trigger | Status |
|---------|--------|
| AI Governance | ‚úÖ AI-first company, foundation models |
| Platform Development | ‚úÖ Major platform launches |
| Leadership Changes | ‚úÖ Recent executive hires |

**Outreach Recommendation:** üî• HIGH PRIORITY - AI governance conversation is highly relevant. New leadership creates opportunity.

---

#### 9. Cellares üü¢ TOP PRIORITY
**Location:** South San Francisco, CA (HQ) + Bridgewater, NJ  
**Status:** Private (IPO preparation announced)

**Recent News (Very Active):**
- **January 2026**: Raised $257M Series D led by BlackRock and Eclipse
- **January 2026**: IND amendment clearance for Cabaletta Bio's Rese-Cel
- **January 2026**: Expanded to European HQ in Netherlands
- **January 2026**: Partnership with City of Hope for solid tumor CAR-T
- **January 2026**: Autolus evaluating Cell Shuttle for AUCATZYL
- **December 2025**: Appointed Ali Soleymannezhad as CCO (from MaxCyte)
- **September 2025**: Added Christopher McDonald (former Kite) to advisory board
- **September 2025**: Selected 5 technology providers for Cell Q expansion
- **May 2025**: First IDMO Smart Factory announced in Japan (with Mitsui Fudosan)
- **April 2025**: FDA Advanced Manufacturing Technology (AMT) Designation
- **April 2025**: Completed manufacturing tech adoption with Cabaletta Bio
- **2024**: $380M worldwide capacity agreement with Bristol Myers Squibb

**GTM Alignment:**
| Trigger | Status |
|---------|--------|
| Recent Funding | ‚úÖ $257M Series D - Jan 2026 |
| FDA Designation | ‚úÖ AMT Designation - April 2025 |
| Cell Therapy Scale-up | ‚úÖ Category-defining IDMO |
| Platform/Systems | ‚úÖ Massive automation needs |
| Leadership Changes | ‚úÖ New CCO, expanding team |
| IPO Preparation | ‚úÖ Announced |
| GxP Requirements | ‚úÖ cGMP manufacturing |

**Outreach Recommendation:** üî•üî• IMMEDIATE PRIORITY - Everything aligns. IPO preparation means documentation, compliance, validation needs. BMS partnership shows they're working with regulated pharma.

---

#### 10. 64x Bio üü¢ HOT PROSPECT
**Location:** Brisbane, CA (1000 Marina Blvd)  
**Status:** Private

**Recent News:**
- **June 2025**: Launched AAV Apex Suite for gene therapy manufacturing
  - Addresses major manufacturing bottleneck
  - Featured at BIO Conference
- Active in AI/ML for manufacturing optimization
- George Church spinout with $55M Series A (2022)
- CEO Alexis Rovner recognized in "20 Under 40" biotech leaders

**GTM Alignment:**
| Trigger | Status |
|---------|--------|
| Gene Therapy Manufacturing | ‚úÖ Core focus |
| AI Governance | ‚úÖ AI-powered cell line engineering |
| GxP Needs | ‚úÖ Manufacturing platform |
| Platform Launch | ‚úÖ AAV Apex Suite 2025 |

**Outreach Recommendation:** üî• HIGH PRIORITY - New product launch, manufacturing focus, likely growing compliance needs.

---

#### 11. Allogene Therapeutics
**Location:** South San Francisco, CA (210 E. Grand Avenue)  
**Status:** Public (NASDAQ: ALLO)

**Recent News:**
- Mentioned extensively in CAR T-cell therapy market reports
- Active in DLBCL, follicular lymphoma markets
- Partnership with Foresight Diagnostics expanding to Europe, UK, Canada, Australia (Feb 2025)
- Active AlloCAR T pipeline (ALPHA3 and RESOLUTION trials)

**GTM Alignment:**
| Trigger | Status |
|---------|--------|
| Clinical Trials | ‚úÖ Active Phase 3 programs |
| Cell Therapy | ‚úÖ Allogeneic CAR-T leader |
| International Expansion | ‚úÖ Ex-US expansion underway |

**Outreach Recommendation:** üü° MODERATE - Established company, may have systems in place. Look for specific needs.

---

#### 12. GRAIL üü¢ SOLID PROSPECT
**Location:** Menlo Park, CA  
**Status:** Public (NASDAQ: GRAL)

**Recent News:**
- **October 2025**: PATHFINDER 2 results announced
  - Galleri test increased cancer detection 7x when added to standard screenings
  - More than half of cancers detected were early stage
  - ~75% of Galleri-detected cancers lack recommended screenings
  - Largest U.S. MCED interventional study
- Multi-Cancer Early Detection (MCED) market leader

**GTM Alignment:**
| Trigger | Status |
|---------|--------|
| AI/ML | ‚úÖ Diagnostic AI platform |
| Regulatory | ‚úÖ FDA pathway navigation |
| Scale-up | ‚úÖ Commercializing Galleri |
| Clinical Data | ‚úÖ Major study results |

**Outreach Recommendation:** üü¢ SOLID - Growing commercial operations, regulatory engagement. LDT/IVD compliance needs.

---

### San Diego

#### 13. National Resilience üü¢ TOP PRIORITY
**Location:** San Diego, CA (HQ) + Cincinnati, OH + Boston  
**Status:** Private

**Recent News:**
- **October 2025**: Announced $825M long-term financing from Oak Hill Advisors
  - Accelerating CDMO strategy
  - Investment in go-forward manufacturing operations
- **March 2025**: Expanded partnership with JobsOhio, Blue Ash facility expansion
- **January 2025**: Partnership with CARGO Therapeutics for allogeneic CAR-T
- **January 2025**: Partnership with Parvus Therapeutics for PVT401 (IBD drug)
- **December 2024**: Appointed William S. Marth as CEO (former pharma exec)
- **October 2024**: Secured funding for domestic pharmaceutical ingredient manufacturing

**GTM Alignment:**
| Trigger | Status |
|---------|--------|
| Recent Funding | ‚úÖ $825M - Oct 2025 |
| Leadership Changes | ‚úÖ New CEO - Dec 2024 |
| Facility Expansion | ‚úÖ Multiple site expansions |
| GxP Manufacturing | ‚úÖ CDMO with complex modalities |
| Platform Needs | ‚úÖ Scaling operations rapidly |

**Outreach Recommendation:** üî•üî• IMMEDIATE PRIORITY - Major funding, new CEO, rapid expansion. CDMO needs enterprise QMS, documentation systems, validation support.

---

#### 14. Fate Therapeutics
**Location:** San Diego, CA (12278 Scripps Summit Drive)  
**Status:** Public (NASDAQ: FATE)

**Recent News:**
- Active iPSC-derived cell therapy platform
- Multiple product candidates: FT819, FT825, FT836, FT839, FT522
- Mentioned in CAR T-cell therapy market reports
- Focus on cancer and autoimmune disease

**GTM Alignment:**
| Trigger | Status |
|---------|--------|
| Cell Therapy | ‚úÖ iPSC platform leader |
| Manufacturing | ‚úÖ Complex manufacturing |
| Clinical Trials | ‚úÖ Multiple active programs |

**Outreach Recommendation:** üü° MODERATE - Established company, may have systems. Look for specific project needs.

---

#### 15. Poseida Therapeutics üî¥ ACQUIRED
**Location:** San Diego, CA (9390 Towne Centre Drive)  
**Status:** **ACQUIRED BY ROCHE** - Now "A Member of the Roche Group"

**Recent Discovery:**
- Poseida is now part of Roche
- Website shows "A Member of the Roche Group"
- Still active in CAR T-cell therapy space

**GTM Alignment:**
May be managed through Roche enterprise agreements now.

**Outreach Recommendation:** üî¥ UPDATE TARGET LIST - Engage through Roche relationship if applicable.

---

#### 16. Capstan Therapeutics üî¥ ACQUIRED
**Location:** San Diego, CA  
**Status:** **ACQUIRED BY ABBVIE** (August 2025)

**Recent News:**
- **August 2025**: AbbVie completed acquisition
- Lead asset CPTX2309 now in Phase 1 for B cell-mediated autoimmune diseases
- First-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T

**GTM Alignment:**
Now part of AbbVie.

**Outreach Recommendation:** üî¥ REMOVE FROM TARGET LIST - Now AbbVie subsidiary.

---

## Part 2: New Logo Opportunities

### Tier 1 - Immediate Priority (Strong GTM Trigger Match)

#### 1. Freenome üî•
**Location:** South San Francisco, CA  
**Funding:** Late-stage, going public via SPAC  
**GTM Triggers:**
- ‚úÖ AI/ML: Partnership with NVIDIA (Jan 2026), deep learning initiatives
- ‚úÖ Major Partnerships: Roche exclusive agreement (Nov 2025), Exact Sciences license (Aug 2025)
- ‚úÖ Leadership: New CEO Aaron Elliott, PhD (Apr 2025), New CFO (May 2025)
- ‚úÖ Going Public: Business combination with Perceptive Capital (Dec 2025)
- ‚úÖ Platform: FLDL multi-cancer detection model

**Why Target:** IPO preparation + Roche partnership = massive compliance documentation needs

---

#### 2. Kyverna Therapeutics üî•
**Location:** Emeryville/Bay Area, CA  
**Funding:** Public (went public 2024)  
**GTM Triggers:**
- ‚úÖ Autoimmune CAR-T: First-mover in autoimmune cell therapy
- ‚ö†Ô∏è Securities Litigation: Class action filed (deadline Feb 2025)
- ‚úÖ New CFO appointed (Jun 2025)
- ‚úÖ Active clinical programs in lupus nephritis, MS, myasthenia gravis

**Why Target:** New public company building infrastructure, legal situation creates compliance urgency

---

#### 3. Cabaletta Bio
**Location:** Philadelphia, PA (works with Western partners)  
**GTM Triggers:**
- ‚úÖ Cell Therapy: CD19-CAR T for autoimmune diseases
- ‚úÖ Manufacturing: Working with Cellares on automated manufacturing
- ‚úÖ IND Clearance: Rese-cel IND amendment cleared (Jan 2026)
- ‚úÖ Clinical Scale-up: Moving toward commercialization

**Why Target:** Cellares partnership suggests openness to innovative solutions

---

#### 4. Recursion Pharmaceuticals
**Location:** Salt Lake City, UT  
**Funding:** Public (NASDAQ: RXRX)  
**GTM Triggers:**
- ‚úÖ AI-Native: Leading AI drug discovery platform
- ‚úÖ Mentioned in AI healthcare market reports
- ‚úÖ Utah's fastest-growing tech

**Why Target:** AI governance, model validation, GxP for AI systems

---

#### 5. Insitro
**Location:** South San Francisco, CA  
**Funding:** Private ($400M+ raised)  
**GTM Triggers:**
- ‚úÖ AI Drug Discovery: Founded by Daphne Koller (Stanford AI pioneer)
- ‚úÖ Speaking at Fortune Brainstorm AI (Dec 2025)
- ‚úÖ Machine learning for biology platform

**Why Target:** AI governance leader, high-profile, regulatory pathway needs

---

### Tier 2 - Monitor Closely (Emerging Opportunities)

#### 6. Cartography Biosciences
**Location:** San Francisco, CA  
**Funding:** $50M+ raised  
**GTM Triggers:**
- ‚úÖ Precision Therapeutics platform
- ‚úÖ CEO Kevin Parker named BioSpace 40 Under 40 (Oct 2025)
- ‚úÖ Target discovery platform

**Why Target:** Growing company with AI-enabled discovery

---

#### 7. Boundless Bio
**Location:** San Diego, CA  
**Funding:** Public (NASDAQ: BOLD)  
**GTM Triggers:**
- ‚úÖ Oncology focus (extrachromosomal DNA)
- ‚úÖ Clinical stage
- ‚úÖ San Diego presence

**Why Target:** Clinical-stage with manufacturing needs

---

#### 8. Exscientia
**Location:** Oxford, UK / US Operations  
**GTM Triggers:**
- ‚úÖ AI Drug Discovery pioneer
- ‚úÖ Named among Fast Company's Most Innovative Biotech
- ‚úÖ Multiple pharma partnerships

**Why Target:** AI governance, model validation needs

---

#### 9. DarwinHealth
**Location:** New York (US ops)  
**GTM Triggers:**
- ‚úÖ Fast Company Top 10 Most Innovative Biotech (Mar 2025)
- ‚úÖ AI-powered precision therapeutics
- ‚úÖ Multiple disease programs

**Why Target:** Emerging AI biotech

---

#### 10. Interius BioTherapeutics
**Location:** Bay Area  
**GTM Triggers:**
- ‚úÖ CAR T-cell therapy developer
- ‚úÖ Mentioned in market reports alongside major players

**Why Target:** Cell therapy manufacturing needs

---

### Tier 3 - Watch List (Research Further)

| Company | Location | Trigger | Notes |
|---------|----------|---------|-------|
| Lyell Immunopharma | South SF | Cell Therapy | Cellares partner |
| CARGO Therapeutics | San Carlos | Cell Therapy | Resilience partner, public |
| Century Therapeutics | Seattle ops | iPSC Cell Therapy | Allogeneic focus |
| Precision BioSciences | Durham | Gene Editing | Active in CAR-T |
| Arcellx | Redwood City | CAR-T | Clinical stage |
| Nkarta | South SF | NK Cell Therapy | Clinical programs |
| ONK Therapeutics | Bay Area | NK Cell Therapy | Emerging |
| Luminary Therapeutics | LA area | Cell Therapy | Multiple mentions |
| Lepton Pharmaceuticals | CA | Lupus | Pipeline company |
| Annexon Biosciences | South SF | Autoimmune | Clinical programs |

---

## Part 3: Recommended Outreach Priorities

### Immediate Action (February 2026)

| Priority | Company | Trigger | Suggested Approach |
|----------|---------|---------|-------------------|
| üî• 1 | **Cellares** | $257M funding, IPO prep, FDA designation | QMS, validation, documentation for commercial scale |
| üî• 2 | **National Resilience** | $825M funding, new CEO, expansion | CDMO quality systems, enterprise documentation |
| üî• 3 | **Tune Therapeutics** | $175M funding, new CEO, clinical start | Clinical manufacturing QC, GxP systems |
| üî• 4 | **Freenome** | Going public, Roche/Exact partnerships | IPO compliance, partnership documentation |
| üî• 5 | **64x Bio** | New product launch, manufacturing | Platform validation, GxP for manufacturing |

### Q1 2026 Nurture

| Company | Trigger | Timing |
|---------|---------|--------|
| Deep Genomics | AI foundation model, exec hires | After platform launch stabilizes |
| Kyverna | Legal situation, new CFO | When litigation settles |
| GRAIL | PATHFINDER 2 results, commercialization | Ongoing relationship |
| Cabaletta Bio | IND clearance, Cellares partnership | Through Cellares connection |

### Target List Updates Required

| Action | Company | Reason |
|--------|---------|--------|
| üî¥ REMOVE | Capstan Therapeutics | Acquired by AbbVie Aug 2025 |
| üî¥ REMOVE | Poseida Therapeutics | Acquired by Roche |
| ‚ö†Ô∏è UPDATE | Atomwise | Rebranded to Numerion Labs |
| ‚ö†Ô∏è MONITOR | Sana Biotechnology | Securities litigation |
| ‚úÖ ADD | Freenome | Going public, major partnerships |
| ‚úÖ ADD | Kyverna Therapeutics | Emerging autoimmune CAR-T |
| ‚úÖ ADD | Cartography Biosciences | Precision therapeutics, growing |

---

## Appendix: GTM Trigger Summary by Company

### AI Governance Triggers
- Freenome (NVIDIA partnership, FLDL model)
- Deep Genomics (REPRESS AI model)
- 64x Bio (AI-powered manufacturing)
- Recursion (AI-native platform)
- Insitro (ML for biology)
- GRAIL (Diagnostic AI)

### Cell Therapy Scale-Up
- Cellares (IDMO, BMS $380M deal)
- National Resilience (CDMO expansion)
- Tune Therapeutics (Clinical start)
- Cabaletta Bio (IND clearance)
- Kyverna (Autoimmune CAR-T)
- 64x Bio (AAV manufacturing)

### Regulatory Pressure / Compliance
- Sana Biotechnology (Securities litigation)
- Kyverna (Securities litigation)
- Cellares (FDA AMT designation)

### Recent Major Funding
- Cellares: $257M Series D (Jan 2026)
- National Resilience: $825M financing (Oct 2025)
- Tune Therapeutics: $175M Series B (Jan 2025)

### Leadership Changes
- Tune Therapeutics: New CEO (Mar 2025)
- National Resilience: New CEO (Dec 2024)
- Freenome: New CEO + CFO (Apr-May 2025)
- Kyverna: New CFO (Jun 2025)
- Cellares: New CCO (Dec 2025)
- Deep Genomics: Executive hires (Apr 2025)

---

*Research compiled: February 3, 2026*  
*Sources: Company websites, PR Newswire, BioPharma Dive, industry news*  
*Note: Web search API unavailable; data gathered via direct website fetching*
